931 The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer

• Published in: International journal of gynecological cancer Vol. 34; no. Suppl 1; pp. A118 - A119
• Main Authors: Park, Eun-Byul, Kim, Jun-Hwan, Kim, Ju-Hyun, Lee, Shin-Wha, Kim, Dae-Yeon, Seo, Dae-Shik, Kim, Jong-Hyeok, Kim, Yong-Man, Park, Jeong-Yeol
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group Ltd 10.03.2024; BMJ Publishing Group LTD
• Subjects: Cervical cancer; Medical prognosis; Poster and E-Posters
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2024-ESGO.215

Introduction/BackgroundThis study aimed to evaluate to prognostic factors and treatment outcomes of first-line paclitaxel and cisplatin plus bevacizumab (TPB), specifically for cervical cancer (CC) stage IVB, in real-world setting.MethodologyWe retrospectively reviewed the patients with CC IVB who received TPB as first-line treatment between December. 2015 and December 2021 in Asan Medical Center (AMC) in South Korea. We collected patients’ data including clinicopathologic characteristics, imaging, detailed chemotherapy history related TPB administration, recurrence, and survival.ResultsIn total, 61 patients were included in this study. Median age was 56 (28–79) years. The most common histologic subtype was squamous cell carcinoma (58.6%). Lung and bone metastasis were confirmed in 23 (37.7%) and 16 (26.2%). Hydronephrosis was observed in 19 (31.1%) patients. The patients received 9 (2–30) cycles of TPB in median and 41% had experienced dose reduction. Best objective response rate of TPB was 88.5%. Metabolic complete and partial remission were observed in 8 and 14 patients, respectively. Most common cause of dose reduction for TPB was azotemia (27.9%). No fistula case was observed during TPB. The median largest dimension of the cervical mass on pre-treatment in imaging was 6.1 (1.3–16.9) cm, whereas the median largest dimension of the smallest cervical mass during treatment in imaging was 1.8 (0–10.0) cm. Recurrence was observed in 51 patients (83.6%) and median progression-free survival (PFS) from TPB start was 11.8 (95% confidence interval [CI], 9.3–14.2). Death was observed in 40 patients (65.6%) and median overall survival was 24.3 (16.9–31.7) months. In univariate analysis, the cervical mass size shrinkage ≤ 70% during TPB was the only prognostic factor for PFS (p = 0.02).ConclusionTPB is effective treatment for CC stage IVB and the level of shrinkage of the cervical mass during TPB might have a prognostic role for PFS.DisclosuresNone.